TY - JOUR
T1 - Human platelet lysate is an alternative to fetal bovine serum for large-scale expansion of bone marrow-derived mesenchymal stromal cells
AU - Gottipamula, Sanjay
AU - Sharma, Archana
AU - Krishnamurthy, Sagar
AU - Majumdar, Anish Sen
AU - Seetharam, Raviraja N.
N1 - Funding Information:
Acknowledgements We are most grateful to KMC blood bank for providing us platelets concentrate for our study and Dr. Swathi Sundar Raj and team for invaluable and critical support during immunosuppressive assay. This work was fully funded by Stempeutics Research Pvt. Ltd., India.
Copyright:
Copyright 2012 Elsevier B.V., All rights reserved.
PY - 2012/7
Y1 - 2012/7
N2 - Human platelet lysate (HPL) was evaluated as an alternative to fetal bovine serum (FBS) in large-scale culturing of bone marrow-derived mesenchymal stromal cells (BM-MSCs) for therapeutic applications. Dulbecco's modified Eagle medium (DMEM)of low glucose (LG) and Knock Out (KO) were used with human platelet lysate (HPL) as LG-HPL and KO-HPL, and with FBS as LG-FBS and KO-FBS to culture the BM-MSCs. HPL at 10 % (v/v) supported BM-MSCs growth and subsequent isolation efficiency generated >90 × 10 6 MSCs in LG-HPL. Population doublings (PDs) and population doubling times of LG-HPL and KO-HPL (PDT) were not significantly different but LG-HPL showed a significant clonogenic potential and HPL cultures had an average PDT of 36. 5 ± 6. 5 h and an average PDs of 5 ± 0. 7/passage. BM-MSCs cultured with LG-HPL had significantly higher immunosuppression compared to LG-FBS, but KO-HPL and KO-FBS-grown cultures were not significantly different. HPL is therefore alternative to FBS for large-scale production of BM-MSCs for therapeutic applications.
AB - Human platelet lysate (HPL) was evaluated as an alternative to fetal bovine serum (FBS) in large-scale culturing of bone marrow-derived mesenchymal stromal cells (BM-MSCs) for therapeutic applications. Dulbecco's modified Eagle medium (DMEM)of low glucose (LG) and Knock Out (KO) were used with human platelet lysate (HPL) as LG-HPL and KO-HPL, and with FBS as LG-FBS and KO-FBS to culture the BM-MSCs. HPL at 10 % (v/v) supported BM-MSCs growth and subsequent isolation efficiency generated >90 × 10 6 MSCs in LG-HPL. Population doublings (PDs) and population doubling times of LG-HPL and KO-HPL (PDT) were not significantly different but LG-HPL showed a significant clonogenic potential and HPL cultures had an average PDT of 36. 5 ± 6. 5 h and an average PDs of 5 ± 0. 7/passage. BM-MSCs cultured with LG-HPL had significantly higher immunosuppression compared to LG-FBS, but KO-HPL and KO-FBS-grown cultures were not significantly different. HPL is therefore alternative to FBS for large-scale production of BM-MSCs for therapeutic applications.
UR - http://www.scopus.com/inward/record.url?scp=84862139313&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862139313&partnerID=8YFLogxK
U2 - 10.1007/s10529-012-0893-8
DO - 10.1007/s10529-012-0893-8
M3 - Article
C2 - 22476583
AN - SCOPUS:84862139313
SN - 0141-5492
VL - 34
SP - 1367
EP - 1374
JO - Biotechnology Letters
JF - Biotechnology Letters
IS - 7
ER -